2016-02-08 20:59:04 UTC

CRC Tumors in IBD Patients Have Unique Genetic Features

Feb. 10, 2016

Gastro findings could be used to develop disease-specific markers for the diagnosis and treatment of patients with IBD and CRC.

IBD patients experience a higher incidence of colorectal cancer (CRC) than the general population. And now a new Gastroenterology article-in-press utilizes whole-exome sequencing analyses to provide a comprehensive look at the genetic landscape of CRC tumors in IBD patients.

The multidisciplinary research team — led by Ana I. Robles, PhD, Giovanni Traverso, MD, PhD, and Ming Zhang, PhD — identified a number of similarities between IBD-associated and sporadic colorectal tumors, indicating that the development of these tumors involves, for the most part, the same cellular pathways.

However, there are striking differences. Mutations in key genes involved in the development and progression of sporadic CRC are uncommonly altered in IBD-CRC, suggesting an underlying difference in mechanism or etiology between IBD-associated and sporadic colorectal tumors.

This in-depth analysis of colorectal tumors associated with IBD demonstrates a unique molecular profile and provides clues to the etiology of CRC in IBD patients. This study also sets the stage for improved early detection of colorectal tumors in IBD patients based on their unique genetic composition, as well as for the tailoring of therapies in this patient population.

Read the full study on the Gastroenterology website (log in required).

More on Colorectal Cancer

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Advocate CMS, close the colonoscopy loophole

March 8, 2018

AGA urges CMS to address the cost sharing problem that arises when screening colonoscopies become diagnostic for Medicare patients.